Claims
- 1. A microcapsule comprising a cross-linked outer wall surrounding a filled inner space, said outer wall resulting from crosslinking between molecules of atelocollagen and polyholoside.
- 2. A microcapsule comprising a cross-linked outer wall surrounding a filled inner space and further comprising an active compound, said outer wall resulting from crosslinking between molecules of atelocollagen and polyholoside.
- 3. A microcapsule comprising a crosslinked outer wall surrounding a filled inner space, said filled inner space comprising a mixture of atelocollagen and polyholoside, said outer wall resulting from crosslinking between molecules of said atelocollagen and said polyholoside.
- 4. A microcapsule comprising a crosslinked outer wall surrounding a filled inner space, said filled inner space comprising a mixture of atelocollagen, polyholoside, and active compound, said active compound being selected from the group consisting of cosmetic, pharmaceutical and food compounds, and said outer wall resulting from crosslinking between molecules of said atelocollagen and said polyholoside.
- 5. The microcapsule of claim 1, 2, 3 or 4, wherein said polyholoside comprises dextran.
- 6. A microcapsule comprising a cross-linked outer wall surrounding an inner space, said outer wall resulting from crosslinking between molecules of atelocollagen and polyholoside, said inner space comprising an encapsulated oily phase.
- 7. A microcapsule comprising a cross-linked outer wall surrounding an inner space and further comprising an active compound, said outer wall resulting from crosslinking between molecules of atelocollagen and polyholoside, said inner space comprising an encapsulated oily phase.
- 8. The microcapsule of claims 1, 2, 3 or 4, wherein the proportion of said polyholoside relative to said atelocollagen can vary from 15 to 50% by weight.
- 9. The microcapsule of claims 1, 2, 3 or 4, wherein said polyholoside is selected from the group of structural glycosaminoglycans consisting of chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, heparin sulfate, keratan sulfate, and heparin, said heparin comprising low molecular weight heparin having a molecular weight ranging from about 2000-10000 or cosmetically or pharmaceutically acceptable salts of heparin.
- 10. The microcapsule of claim 9, wherein said cosmetically or pharmaceutically acceptable salts are calcium or sodium salts.
Priority Claims (1)
Number |
Date |
Country |
Kind |
89 01221 |
Jan 1989 |
FRX |
|
Parent Case Info
This is a continuation of Ser. No. 749,909, filed on Aug. 26, 1991, and abandoned, which is a continuation-in-part of application Ser. No. 07/336,711, filed on Apr. 12, 1989, now abandoned.
US Referenced Citations (5)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0268421 |
May 1988 |
EPX |
Non-Patent Literature Citations (1)
Entry |
"Utilising Collagen in Drug Formulation", Manufacturing Chemist, vol. 57, No. 9, Sep. 1986, pp. 64-65, 67, London, Great Britain. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
749909 |
Aug 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
336711 |
Apr 1989 |
|